Daniel van den Bergh

Daniel is a Senior Investment Director at Endeavour Vision, focusing on digital health, enterprise healthcare IT, and tech-enabled healthcare services companies. Daniel brings 15+ years of experience in healthcare venture capital, startup operations, and investment banking. He advised on the investment in HealthJoy. He is based in San Francisco, US.

Before joining Endeavour Vision, Daniel was a Director at Kaiser Permanente Ventures where his investment work included companies across the healthcare technology landscape: NOCD, Ordr, Nuvolo (acquired), NextHealth (acquired), Collective Medical (acquired), Protenus, Talix (acquired), Vesta Healthcare, Ginger (merged), Leiter’s (acquired), and Health Catalyst (IPO); he was board director or observer with six of these portfolio companies.

Previously, Daniel was Director of Strategy & Operations at Lumiata, a clinical analytics platform that predicts disease risk. Earlier in his career, Daniel worked for Safeguard Scientifics, a healthcare and technology venture capital firm where he performed investment analyses in healthcare IT, specialty pharmaceuticals, diagnostics, and medical devices. Daniel began his career in healthcare investment banking where he focused on cross-border transactions in the US, Europe, and the Middle East at Citigroup and EC Mergers & Acquisitions.

Daniel holds an MBA in Healthcare Management from The Wharton School and a BS in Biological Engineering from Cornell University.